Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.

@article{Lang2013TwoyearSA,
  title={Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.},
  author={Gabriele Elisabeth Lang and Andr{\'a}s Berta and Bora Eldem and Christian Simader and Dianne M Sharp and Frank G. Holz and Florian Sutter and Ortrud Gerstner and Paul Mitchell},
  journal={Ophthalmology},
  year={2013},
  volume={120 10},
  pages={2004-12}
}
OBJECTIVE To evaluate the 2-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema (DME). DESIGN Twenty-four-month, open-label, multicenter, Phase IIIb extension study. PARTICIPANTS Two hundred forty of 303 patients with visual impairment due to DME who completed the RESTORE core study and entered the extension. METHODS All patients were eligible to receive ranibizumab 0.5 mg pro re nata (PRN) from month 12 (end of core study) to month 36 based on best-corrected visual… CONTINUE READING
34 Citations
13 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Diabetic Retinopathy Clinical Research Network

  • Committee, MJ Elman, NM Bressler, H Qin
  • Ophthalmology
  • 2011
Highly Influential
12 Excerpts

Diabetic Retinopathy Clinical Research

  • MJ Elman, LP Aiello, RW Beck
  • Ophthalmology
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…